Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06789198 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Peptide Vaccine for Fibrolamellar Hepatocellular Carcinoma Patients and Other Tumor Entities Carrying the Driver Fusion DNAJB1-PRKACA

Study acronym: FusionVAC22_02
StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 11 words
    • Study description shortened, about 34 words
    • Site details revised at 1 of 2 sites
    v6
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jun 1, 2025 to Jul 8, 2025
    • Site details revised at 2 of 2 sites
    v5
  3. Start date: Apr 1, 2025 to Jun 1, 2025v4
  4. Primary endpoints: 1 to 2
    • Study sites: 1 to 2
    • Eligibility criteria expanded, about 22 words
    v3
  5. Eligibility criteria revised
    • Study description expanded, about 198 words
    • Study title shortened, about 3 words
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of this clinical trial is to evaluate the immunogenicity along with safety and toxicity as well as first efficacy of a DNAJB1-PRKACA fusion transcript-based peptide vaccine (Fusion-VAC-XS15) in patients with FL-HCC or other cancer entities carrying the DNAJB1-PRKACA fusion transcript as adjuvant treatment
Trial Details
NCT Number NCT06789198
Lead Sponsor University Hospital Tuebingen
Conditions
(from sponsor)		 Fibrolamellar Hepatocellular Carcinoma (FLC)
Related terms Fibrolamellar hepatocellular carcinoma
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov